Among these modalities, checkpoint blockade immunotherapies, specifically those targeting programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (PD-L1), have been proven to provide long-term clinical benefits to patients with non-small cell lung cancer (NSCLC) [4, 5]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.